المؤلفون: Peter-Derex, Laure, Philippeau, Frédéric, Garnier, Pierre, André-Obadia, Nathalie, Boulogne, Sébastien, Catenoix, Hélène, Convers, Philippe, Mazzola, Laure, Gouttard, Michel, Esteban, Maud, Fontaine, Julia, Mechtouff, Laura, Ong, Elodie, Cho, Tae-Hee, Nighoghossian, Norbert, Perreton, Nathalie, Termoz, Anne, Haesebaert, Julie, Schott, Anne-Marie, Rabilloud, Muriel, Pivot, Christine, Dhelens, Carole, Filip, Andrea, Berthezène, Yves, Rheims, Sylvain, Boutitie, Florent, Derex, Laurent

المساهمون: Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Croix-Rousse CHU - HCL, Hospices Civils de Lyon (HCL), Centre Hospitalier Fleyriat Bourg en Bresse (CHBBF), Centre Hospitalier Universitaire de Saint-Etienne CHU Saint-Etienne (CHU ST-E), Service de neurologie fonctionnelle et d'épileptologie Hôpital Pierre Wertheimer-HCL, Hôpital neurologique et neurochirurgical Pierre Wertheimer CHU - HCL, Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Research on Healthcare Performance (RESHAPE - Inserm U1290 - UCBL1), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Service de Biostatistiques Lyon, Hôpital Edouard Herriot CHU - HCL, Modeling & analysis for medical imaging and Diagnosis (MYRIAD), Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), The study was funded by the French Ministry of Health (PHRC-I, 2013).

المصدر: ISSN: 1474-4422.

مصطلحات موضوعية: [SDV]Life Sciences [q-bio]

الوصف: International audience ; BACKGROUND: The incidence of early seizures (occurring within 7 days of stroke onset) after intracerebral haemorrhage reaches 30% when subclinical seizures are diagnosed by continuous EEG. Early seizures might be associated with haematoma expansion and worse neurological outcomes. Current guidelines do not recommend prophylactic antiseizure treatment in this setting. We aimed to assess whether prophylactic levetiracetam would reduce the risk of acute seizures in patients with intracerebral haemorrhage. METHODS: The double-blind, randomised, placebo-controlled, phase 3 PEACH trial was conducted at three stroke units in France. Patients (aged 18 years or older) who presented with a non-traumatic intracerebral haemorrhage within 24 h after onset were randomly assigned (1:1) to levetiracetam (intravenous 500 mg every 12 h) or matching placebo. Randomisation was done with a web-based system and stratified by centre and National Institutes of Health Stroke Scale (NIHSS) score at baseline. Treatment was continued for 6 weeks. Continuous EEG was started within 24 h after inclusion and recorded over 48 h. The primary endpoint was the occurrence of at least one clinical seizure within 72 h of inclusion or at least one electrographic seizure recorded on continuous EEG, analysed in the modified intention-to-treat population, which comprised all patients who were randomly assigned to treatment and who had a continuous EEG performed. This trial was registered at ClinicalTrials.gov, NCT02631759, and is now closed. Recruitment was prematurely stopped after 48% of the recruitment target was reached due to a low recruitment rate and cessation of funding. FINDINGS: Between June 1, 2017, and April 14, 2020, 50 patients with mild-to-moderate severity intracerebral haemorrhage were included: 24 were assigned to levetiracetam and 26 to placebo. During the first 72 h, a clinical or electrographic seizure was observed in three (16%) of 19 patients in the levetiracetam group versus ten (43%) of 23 patients in the ...

العلاقة: inserm-03833172; https://inserm.hal.science/inserm-03833172Test; https://inserm.hal.science/inserm-03833172/documentTest; https://inserm.hal.science/inserm-03833172/file/1-s2.0-S1474442222002356-main.pdfTest

الإتاحة: https://doi.org/10.1016/s1474-4422Test(22)00235-6
https://inserm.hal.science/inserm-03833172Test
https://inserm.hal.science/inserm-03833172/documentTest
https://inserm.hal.science/inserm-03833172/file/1-s2.0-S1474442222002356-main.pdfTest

المؤلفون: Peter-Derex, Laure, Philippeau, Frédéric, Garnier, Pierre, André-Obadia, Nathalie, Boulogne, Sébastien, Catenoix, Hélène, Convers, Philippe, Mazzola, Laure, Gouttard, Michel, Esteban, Maud, Fontaine, Julia, Mechtouff, Laura, Ong, Elodie, Cho, Tae-Hee, Nighoghossian, Norbert, Perreton, Nathalie, Termoz, Anne, Haesebaert, Julie, Schott, Anne-Marie, Rabilloud, Muriel, Pivot, Christine, Dhelens, Carole, Filip, Andrea, Berthezène, Yves, Rheims, Sylvain, Boutitie, Florent, Derex, Laurent

المساهمون: Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), Service de Biostatistiques Lyon

المصدر: ISSN: 1474-4422.

مصطلحات موضوعية: [STAT]Statistics [stat]

الوصف: International audience

العلاقة: hal-04385491; https://hal.science/hal-04385491Test

الإتاحة: https://doi.org/10.1016/S1474-4422Test(22)00235-6
https://hal.science/hal-04385491Test

المؤلفون: Bani-Sadr, Alexandre, Cho, Tae-Hee, Cappucci, Matteo, Hermier, Marc, Ameli, Roxana, Filip, Andrea, Riva, Roberto, Derex, Laurent, de Bourguignon, Charles, Mechtouff, Laura, Eker, Omer, Nighoghossian, Norbert, Berthezène, Yves

المساهمون: Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Modeling & analysis for medical imaging and Diagnosis (MYRIAD), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), ANR-16-RHUS-0009,MARVELOUS,MARVELOUS(2016)

المصدر: ISSN: 1759-8478.

مصطلحات موضوعية: [SDV]Life Sciences [q-bio]

الوصف: International audience ; Aims To evaluate the performance of three MR perfusion software packages (A: RAPID; B: OleaSphere; and C: Philips) in predicting final infarct volume (FIV). Methods This cohort study included patients treated with mechanical thrombectomy following an admission MRI and undergoing a follow-up MRI. Admission MRIs were post-processed by three packages to quantify ischemic core and perfusion deficit volume (PDV). Automatic package outputs (uncorrected volumes) were collected and corrected by an expert. Successful revascularization was defined as a modified Thrombolysis in Cerebral Infarction (mTICI) score ≥2B. Uncorrected and corrected volumes were compared between each package and with FIV according to mTICI score. Results Ninety-four patients were included, of whom 67 (71.28%) had a mTICI score ≥2B. In patients with successful revascularization, ischemic core volumes did not differ significantly from FIV regardless of the package used for uncorrected and corrected volumes (p>0.15). Conversely, assessment of PDV showed significant differences for uncorrected volumes. In patients with unsuccessful revascularization, the uncorrected PDV of packages A (median absolute difference −40.9 mL) and B (median absolute difference −67.0 mL) overestimated FIV to a lesser degree than package C (median absolute difference −118.7 mL; p=0.03 and p=0.12, respectively). After correction, PDV did not differ significantly from FIV for all three packages (p≥0.99). Conclusions Automated MRI perfusion software packages estimate FIV with high variability in measurement despite using the same dataset. This highlights the need for routine expert evaluation and correction of automated package output data for appropriate patient management.

العلاقة: hal-03703407; https://hal.science/hal-03703407Test

الإتاحة: https://doi.org/10.1136/neurintsurg-2022-018674Test
https://hal.science/hal-03703407Test